Abstract: Methods and novel intermediates for the preparation of and the treatment with acyclic nucleoside derivatives of the formula: where one of R1 and R2 is an amino acid acyl group and the other of R1 and R2 is a —C(O)C3—C21 saturated or monounsaturated, optionally substituted alkyl and R3 is OH or H.

Abstract: Methods and novel intermediates for the preparation of and the treatment with acyclic nucleoside derivatives of the formula: where one of R1 and R2 is an amino acid acyl group and the other of R1 and R2 is a —C(O)C3-C21 saturated or monounsaturated, optionally substituted alkyl and R3 is OH or H.

Abstract: Methods and novel intermediates for the preparation of and the treatment with acyclic nucleoside derivatives of the formula: where one of R1 and R2 is an amino acid acyl group and the other of R1 and R2 is a —C(O)C3-C21 saturated or monounsaturated, optionally substituted alkyl and R3 is OH or H.

Abstract: Methods and novel intermediates for the preparation of and the treatment with acyclic nucleoside derivatives of the formula: where one of R1 and R2 is an amino acid acyl group and the other of R1 and R2 is a —C(O)C3-C21 saturated or monounsaturated, optionally substituted alkyl and R3 is OH or H.

Abstract: Compounds of the formula I: wherein Rx is cyano or bromo; R1 is halo; R2 is C114 C3 alkyl, and pharmaceutically acceptable salts and prodrugs thereof have activity as antiretrovirals.

Abstract: Methods and novel intermediates for the preparation of and the treatment with acyclic nucleoside derivatives of the formula: 1

Abstract: Methods and novel intermediates for the preparation of and the treatment with acyclic nucleoside derivatives of the formula: where one of R1 and R2 is an amino acid acyl group and the other of R1 and R2 is a —C(O)C3-C21 saturated or monounsaturated, optionally substituted alkyl and R3 is OH or H.

Abstract: Compounds of the formula I: 1

Abstract: Compounds of the Formula I where one of R1 and R2 is —C(O)CH(CH(CH3)2)NH2 or —C(O)CH(CH(CH3)CH2CH3)NH2; the other of R1 and R2 is —C(═O)C3-C21 saturated or monounsaturated, optionally substituted alkyl; and R3 is OH or H; and pharmaceutically acceptable salts thereof have utility as enhanced bioavailability antivirals against herpes and retroviral infections.

Abstract: Methods and novel intermediates for the preparation of and the treatment with acyclic nucleoside derivatives of the formula: 1

Abstract: Compounds of formula (I): wherein Rx is cyano or bromo; R1 is halo; R2 is C1-C3 alkyl, and pharmaceutically acceptable salts and prodrugs thereof have activity as antiretrovirals.

Abstract: Compounds of the Formula I where one of R1 and R2 is —C(O)CH(CH(CH3)2)NH2 or —C(O)CH(CH(CH3)CH2CH3)NH2; the other of R1 and R2 is —C(═O)C3-C21 saturated or monounsaturated, optionally substituted alkyl; and R3 is OH or H; and pharmaceutically acceptable salts thereof have utility as enhanced bioavailability antivirals against herpes and retroviral infections.

Abstract: Compounds of the Formula I ##STR1## where one of R.sub.1 and R.sub.2 is --C(O)CH(CH(CH.sub.3).sub.2)NH.sub.2 or --C(O)CH(CH(CH.sub.3)CH.sub.2 CH.sub.3)NH.sub.2;the other of R.sub.1 and R.sub.2 is --C(.dbd.O)C.sub.3 -C.sub.21 saturated or monounsaturated, optionally substituted alkyl; andR.sub.3 is OH or H;and pharmaceutically acceptable salts thereof have utility as enhanced bioavailability antivirals against herpes and retroviral infections.

Abstract: A process for the production of a 5-7 membered ring cyclic sulfonium salt compound, including a 5-7 membered ring cyclic sulfonium salt compound having a non-nucleophilic anion, is described. Members of the latter group are potentially useful as initiators for cationic polymerizations. The process comprises reacting a 1.4-, 1.5-, or 1.6-diol compound or a 5-7 membered ring cyclic ether compound with a mercapto compound and a strong protonic acid yielding the cyclic sulfonium salt compound. Some compounds described are also novel compounds per se.